Results 151 to 160 of about 4,640 (210)

Focusing on Selinexor for Holding and Bridging Prior to CAR-T in Relapsed/Refractory Multiple Myeloma

Journal of Clinical Medicine
Background: The remarkable efficacy of B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell therapy (CAR-T) has had a significant impact on treatment strategies for relapsed/refractory multiple myeloma (RRMM).
Jack Khouri, D. Sborov, A. Rossi, Thomas Martin, T. Kashyap, T. Mark, Muhamed Baljevic   +6 more
semanticscholar   +1 more source

Phase 1 trial of selinexor in pediatric recurrent/refractory solid and CNS tumors (ADVL1414): A Children’s Oncology Group Phase 1 Consortium Trial

Clinical Cancer Research
Background: Selinexor is a first-in-class, central nervous system (CNS)-penetrant, oral inhibitor of exportin 1 (XPO1), the main nuclear exporter of many key tumor suppressors.
Adam L Green, C. Minard, Xiao-Wei Liu, Stephanie L. Safgren, Kerice Pinkney, L. Harris, Gabrielle Link, J. DeSisto, Stephan D. Voss, Marvin D. Nelson, J. Reid, E. Fox, B. Weigel, J. Glade Bender   +13 more
semanticscholar   +1 more source

From mechanistic synergy to clinical breakthrough: Updated results from a phase II Trial of HD-MTX, selinexor, and zanubrutinib in CNS lymphoma

Blood
Central nervous system lymphoma(CNSL) is an aggressive extranodal non-Hodgkin lymphoma, most commonly classified as diffuse large B-cell lymphoma (DLBCL).
Li Li, B. Pan, Kaiyi Liu, Wenjing Yang, Xin Gao, Qi Zhang, Zhi-Jia Zhao, Yinuo Cai, Xiao-Bo Wang   +8 more
semanticscholar   +1 more source

Primary analysis of the phase 3 randomized trial of selinexor and lenalidomide versus lenalidomide alone as maintenance therapy post autologous stem cell transplant for patients with newly diagnosed multiple myeloma (ALLG MM23; SEALAND)

Blood
Selinexor (S) is an oral selective exportin 1 inhibitor approved in relapsed multiple myeloma (MM) in combination with bortezomib (V) and dexamethasone (d).
M. Rees, M. Lasica, A. Kalff, Michael Low, R. Harrup, Hock-Choong Lai, M. Sidiqi, Nicole Wong Doo, D. Routledge, J. Hocking, P. Campbell, Jessica M. Heenan, N. Horvath, Nicole Chien, William E. P. Renwick, G. McCaughan, Richard Eek, Douglas S. Lenton, S. G. Gazdar, Deepmala Mazumdar, B. Butcher, P. Mollee, H. Quach   +22 more
semanticscholar   +1 more source

Selinexor: First Global Approval

Drugs, 2019
Selinexor (XPOVIO™) is a first-in-class, oral, small molecule Exportin-1 (XPO1) inhibitor that is being developed by Karyopharm Therapeutics for the treatment of cancer. Selinexor (in combination with dexamethasone) received accelerated approval in the USA in July 2019 for the treatment of adult patients with relapsed or refractory multiple myeloma ...
openaire   +2 more sources

Selinexor, mezigdomide, and dexamethasone in patients with Relapsed/Refractory multiple myeloma who relapsed or are ineligible for T-cell–redirecting therapy: Stomp Phase 1 results

Blood
CAR T and bispecific antibody treatment for relapsed/refractory multiple myeloma (RRMM) show promising clinical activity, but most patients (pts) relapse. Emerging clinical data indicate that serial and/or prolonged T-cell–redirecting therapy (TCRT)
Clifton C. Mo, Cristina Gasparetto, Cristiana Costa, A. Cowan, T. Mark, Yi Chai, T. Kashyap, J. Katz, M. Amatangelo, P. Richardson   +9 more
semanticscholar   +1 more source

Selinexor

Reactions Weekly, 2022
openaire   +2 more sources

Preliminary results of first-line selinexor plus R-CHOP in TP53-mutated diffuse large B-cell lymphoma (Smart trial): A single-arm, phase II trial

Blood
Background: TP53 mutations, occurring in approximately 20% of diffuse large B-cell lymphoma (DLBCL) cases, are associated with inferior response and poor prognosis following standard first-line R-CHOP therapy. Selinexor, an oral selective inhibitor
Q. Cai, Yi Xia, Qihua Zou, Jianbo Liu, Zijian Li, S. Bai, Runhui Zheng, Shuling Zhang, Bing Bai, X. Fang, Xiao-Xiao Wang, M. Nie, Hang Yang   +12 more
semanticscholar   +1 more source

XPO1 inhibition by selinexor blocks nucleo-cytoplasmic trafficking of multiple members of the NF-kb family in MPN cell lines and primary myelofibrosis cells

Blood
Introduction: Selinexor, a first-in-class oral selective XPO1 inhibitor, in combination with ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis (MF) has shown rapid, deep, and sustained spleen and symptom responses with associated ...
A. Pomicter, Kristin Starr, Yu-Rong Ouyang, Joshua Monts, J. Marvin, Andrea A. Ellero, Christopher J. Walker, S. Tantravahi   +7 more
semanticscholar   +1 more source

Selinexor in combination with venetoclax and azacitidine for newly diagnosed (ND) unfit Acute Myeloid Leukemia (AML): A multicenter, open-label prospective study

Blood
Introduction： The triple regimen of selinexor, venetoclax, and azacytidine (SAV) has demonstrated favorable results in AML patients (pts) with severe co-morbidities in real-world settings.
Li-Gen Liu, Li Yang, Fangli Chen, Li Chang, Limin Zhao, Xiang Zhou, Chunrong Ying, Ying-Ting Lu, Hong Liang, Yuan-Song Bai, Wen-Zhong Wu, Xiao-Jing Yan, Jin-Hai Ren, Si Li, Yang Yu, Laigen Tong, D. Pan   +16 more
semanticscholar   +1 more source